0001214659-24-004302.txt : 20240311
0001214659-24-004302.hdr.sgml : 20240311
20240311103453
ACCESSION NUMBER: 0001214659-24-004302
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230310
FILED AS OF DATE: 20240311
DATE AS OF CHANGE: 20240311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wargacki Stephen
CENTRAL INDEX KEY: 0001960165
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38599
FILM NUMBER: 24736919
MAIL ADDRESS:
STREET 1: C/O AQUESTIVE THERAPEUTICS, INC.
STREET 2: 30 TECHNOLOGY DRIVE
CITY: WARREN
STATE: NJ
ZIP: 07059
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aquestive Therapeutics, Inc.
CENTRAL INDEX KEY: 0001398733
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 208623253
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 30 TECHNOLOGY DRIVE
CITY: WARREN
STATE: NJ
ZIP: 07059
BUSINESS PHONE: 908-941-1900
MAIL ADDRESS:
STREET 1: 30 TECHNOLOGY DRIVE
CITY: WARREN
STATE: NJ
ZIP: 07059
FORMER COMPANY:
FORMER CONFORMED NAME: MonoSol Rx, Inc.
DATE OF NAME CHANGE: 20070507
4
1
marketforms-64695.xml
PRIMARY DOCUMENT
X0508
4
2023-03-10
0001398733
Aquestive Therapeutics, Inc.
AQST
0001960165
Wargacki Stephen
C/O AQUESTIVE THERAPEUTICS, INC.
30 TECHNOLOGY DRIVE
WARREN
NJ
07059
false
true
false
false
SVP, Research & Development
0
Common Stock
2023-03-10
4
F
false
1981
.7937
D
158419
D
Common Stock
2024-03-07
4
A
false
112500
0
A
270919
D
Non-Qualified Stock Option (right to buy)
5.68
2024-03-07
4
A
false
56250
0
A
2034-03-07
Common Stock
56250
56250
D
Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.
The original Form 3, filed on 1/1/23, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the inclusion of shares vested that occurred on 3/10/22 as a total of 4,663 shares vested and owned when in fact 3,107 shares of the Issuer's common stock were owned, net of taxes withheld. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of shares reported as beneficially owned by the reporting person by 1,556 shares reflecting share withheld for the payment of taxes.
The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
/s/ Lori Braender, as Attorney-In-Fact
2024-03-11